CanSino Biologics Inc.’s $165 Million H-Share Listing

Sidley advised CanSino Biologics Inc. (HKEX: 6185) as the Hong Kong and U.S. counsel in its HK$1.25 billion (approximately US$160.5 million) global offering and listing of H-Shares on the Main Board of the Stock Exchange of Hong Kong Limited.

Morgan Stanley Asia Limited and CLSA Capital Markets Limited acted as joint sponsors in this transaction.

CanSino Biologics Inc. is a bio-tech leader in research and development, manufacturing and commercialization of vaccine products for human use in China.

The Sidley team was led by partners Mengyu Lu (Picture) and Kefei Li, with support from counsel Chen Yang, associates Angela Zhang and Samantha Peng, and China advisors Guanlin Wang and Rock Liu. Legal managers Jenny Han and Ying Liu and legal assistants Junyi Li and Meiyi Li also provided assistance.

Involved fees earner: Kefei Li – Sidley Austin LLP; Mengyu Lu – Sidley Austin LLP; Samantha Peng – Sidley Austin LLP; Guanlin Wang – Sidley Austin LLP; Chen Yang – Sidley Austin LLP; Angela Zhang – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: CanSino Biologics Inc. ;


Author: Michael Patrini